French translation and validation of the mPCOSQ quality-of-life questionnaire for women with PCOS.
Official title: Translation and Validation of the French Version of the Health-related Quality of Life Questionnaire for the Polycystic Ovary Syndrome: the mPCOSQ-F.
Run by CHU de Reims · NCT07016035 · Data updated 2026-11-12
This project tests a French version of the mPCOSQ to see if it reliably measures health-related quality of life in French-speaking women with PCOS aged 18–45.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 350 (estimated) |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Status | Recruiting |
| Started | May 12, 2025 |
| Main results expected | May 12, 2027 |
| Study ends | May 12, 2027 |
| Registry record updated | August 7, 2025 |
| Trial ID | NCT07016035 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
French-fluent women aged 18–45 with a PCOS diagnosis per the 2023 international criteria, not pregnant or breastfeeding, and able to consent and participate are ideal candidates.
✕Probably not a fit
Women with adrenal hyperplasia, androgen-producing tumors, Cushing's syndrome, thyroid disorders, those who are pregnant or breastfeeding, or those under legal protection are excluded and may not benefit from this questionnaire validation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, observational, bicentric project translated the mPCOSQ from English into French and conducted a pre-test phase with phone interviews of the first 30 respondents to check face validity and feasibility. Enrolled French-speaking women aged 18–45 with PCOS complete the mPCOSQ-F and the generic SF-36 at baseline. Participants complete the mPCOSQ-F again after 1–2 weeks to determine test–retest reliability. The final phase compares the mPCOSQ-F results to SF-36 scores and examines internal consistency, reliability, and construct validity.
Why it matters
Potential benefit: If successful, clinicians and researchers will have a validated French tool to measure health-related quality of life in women with PCOS, supporting better symptom tracking and patient-centered care.
How similar studies have gone: Translations and validations of the PCOSQ/mPCOSQ in other languages have generally shown good reliability and validity, so this questionnaire-based approach is well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Women aged 18 to 45 * Fluent in french * Having a diagnosis of PCOS according to the international recommendations published in 2023 * Willing to participate in the study * Affiliated to the french social security system Exclusion criteria: * Diagnosis of adrenal hyperplasia, androgen-producing tumor, Cushing's syndrome, or thyroid disorder * Pregnancy or breast-feeding * Under legal protection
Where it's running
-
Damien JOLLY
Reims, France Recruiting
Study contacts
- Study coordinator: Sara BARRAUD
- Email: sbarraud@chu-reims.fr
- Phone: 03 10 73 63 82
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.